FDA Approves First FET-PET Imaging Agent for Brain Cancer

The FDA has approved Pixclara (floretyrosine F 18), the first amino acid PET drug for imaging gliomas (brain cancer) in adults and pediatric patients aged one month and older. This approval addresses a significant unmet need, providing a crucial tool for differentiating recurrent or progressive glioma from treatment-related changes. Its availability aligns U.S. practice with international guidelines, enhancing diagnostic capabilities.